Fusion Pharm Revenue vs. Earnings Per Share
| FSPM Stock | USD 0.0001 0.00 0.00% |
Total Revenue | First Reported 2010-12-31 | Previous Quarter 683.6 K | Current Value 717.7 K | Quarterly Volatility 183.3 K |
For Fusion Pharm profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Fusion Pharm to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Fusion Pharm utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Fusion Pharm's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Fusion Pharm over time as well as its relative position and ranking within its peers.
Fusion |
Is Consumer Staples Distribution & Retail space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fusion Pharm. If investors know Fusion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fusion Pharm listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.15) | Revenue Per Share 0.133 | Return On Assets (1.38) |
The market value of Fusion Pharm is measured differently than its book value, which is the value of Fusion that is recorded on the company's balance sheet. Investors also form their own opinion of Fusion Pharm's value that differs from its market value or its book value, called intrinsic value, which is Fusion Pharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fusion Pharm's market value can be influenced by many factors that don't directly affect Fusion Pharm's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fusion Pharm's value and its price as these two are different measures arrived at by different means. Investors typically determine if Fusion Pharm is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fusion Pharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Fusion Pharm Earnings Per Share vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Fusion Pharm's current stock value. Our valuation model uses many indicators to compare Fusion Pharm value to that of its competitors to determine the firm's financial worth. Fusion Pharm is rated as one of the top companies in revenue category among its peers. It also is one of the top stocks in earnings per share category among its peers . At this time, Fusion Pharm's Total Revenue is very stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Fusion Pharm by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Fusion Revenue vs. Competition
Fusion Pharm is rated as one of the top companies in revenue category among its peers. Market size based on revenue of Consumer Staples industry is currently estimated at about 385.94 Million. Fusion Pharm adds roughly 594,397 in revenue claiming only tiny portion of stocks in Consumer Staples industry.
Fusion Earnings Per Share vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Fusion Pharm |
| = | 594.4 K |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Fusion Pharm |
| = | (0.15) X |
Earnings per Share is one of the most critical measures of the firm's current share price and is used by investors to determine the overall company profitability, especially when compared to the EPS of similar companies.
Fusion Earnings Per Share Comparison
Fusion Pharm is currently under evaluation in earnings per share category among its peers.
Fusion Pharm Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Fusion Pharm, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Fusion Pharm will eventually generate negative long term returns. The profitability progress is the general direction of Fusion Pharm's change in net profit over the period of time. It can combine multiple indicators of Fusion Pharm, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Operating Income | -9.1 K | -9.6 K | |
| Net Loss | -37.9 K | -36 K | |
| Income Before Tax | -37.9 K | -36 K | |
| Total Other Income Expense Net | -8.2 K | -7.7 K | |
| Net Loss | -37.9 K | -36 K | |
| Net Loss | -37.9 K | -36 K | |
| Change To Netincome | 59.3 K | 62.2 K |
Fusion Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Fusion Pharm. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Fusion Pharm position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Fusion Pharm's important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in Fusion Pharm without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Equity Analysis Now
Equity AnalysisResearch over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |
| All Next | Launch Module |
Use Investing Themes to Complement your Fusion Pharm position
In addition to having Fusion Pharm in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Currency Funds Thematic Idea Now
Currency Funds
Funds or Etfs investing in a single currency or combination of currencies from different countries in order to replicate respective foreign exchange markets. The Currency Funds theme has 41 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Currency Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Investing Opportunities. To learn how to invest in Fusion Stock, please use our How to Invest in Fusion Pharm guide.You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
To fully project Fusion Pharm's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Fusion Pharm at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Fusion Pharm's income statement, its balance sheet, and the statement of cash flows.